Skip to main content
Premium Trial:

Request an Annual Quote

MDx Firm Prolias Licenses MiRNA IP from Cornell

NEW YORK (GenomeWeb News) – Molecular diagnostics company Prolias Technologies today announced it has licensed intellectual property covering microRNA-based diagnostics from Cornell University.

The technologies were developed at the Weill Cornell Medical College. The first series of IP includes a panel called Thymira that differentiates malignant from benign indeterminate thyroid nodules. Prolias, which said it anticipates commercially launching the panel in the coming months, also has licensed an algorithm to interpret results.

According to the New York-based company, more than 450,000 thyroid nodule biopsies are performed annually in the US to determine which ones are cancerous. Of that, about 30 percent are classified as indeterminate, requiring surgery and broader pathology for a complete diagnosis. About 75 percent of the surgically affected nodules, however, are ultimately classified as benign.

Thymira is aimed at eliminating the need for surgery to clarify nodules of indeterminate status, Prolias said.

In addition to Thymira, Prolias has licensed Armira, a miRNA technology to non-invasively monitor acute kidney rejection after transplantation. The company did not elaborate on its commercialization plans for Armira.

Financial terms of licensing deal were not disclosed.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.